Updesh Bedi, MD
Interventional Cardiology · Gretna, LANPI 1669678892
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Inari Medical, Inc. at 34.1% of the total.
Across 416 payments — averaging $134.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$19K
- Stryker$14K
- Medtronic$4K
- Abbott$4K
- Penumbra, Inc.$3K
- Philips North America LLC$3K
- plus $10K from 26 others
What the payments were for
- Consulting fees$12,92823%
- Speaking & faculty fees$13,50024%
- Travel & lodging$7,89814%
- Food & beverage$21,65539%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 78 | $19,109 |
| Stryker | 21 | $13,645 |
| Medtronic(2 entities) | 40 | $4,482 |
| Abbott | 37 | $3,512 |
| Penumbra, Inc. | 15 | $2,795 |
| Philips North America LLC | 33 | $2,744 |
| Boston Scientific | 33 | $2,072 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $1,344 |
| Bard Peripheral Vascular, Inc. | 8 | $787 |
| Novartis | 56 | $737 |
| Kestra Medical Technology Services, Inc. | 11 | $651 |
| Cardiovascular Systems Inc. | 5 | $590 |
| Shockwave Medical, Inc | 5 | $356 |
| Amgen | 3 | $336 |
| Pfizer | 7 | $320 |
| Abiomed | 3 | $305 |
| Inquis Medical, Inc. | 3 | $283 |
| Contego Medical, Inc | 2 | $251 |
| Terumo Medical Corporation | 5 | $245 |
| Johnson & Johnson | 10 | $235 |
| Endologix LLC | 1 | $218 |
| Cook Medical LLC | 1 | $182 |
| Edwards Lifesciences | 1 | $159 |
| Boehringer Ingelheim | 4 | $153 |
| Itamar Medical Inc | 1 | $119 |
| Inspire Medical Systems, Inc. | 1 | $102 |
| Imperative Care, Inc | 2 | $100 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Siemens Medical Solutions USA, Inc. | 2 | $46 |
| Novo Nordisk | 1 | $32 |
| Sanofi | 1 | $28 |
| Osprey Medical Inc | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$30,661
- CT THROMBECTOMY SYSTEM KIT$30,358
- Indigo System$2,540
- IN.PACT Admiral$1,729
- Omnilink Elite vascular stent system$1,364
- AngioJet Ultra 5000A$995
- CARDIOMEMS$750
- IGT D Coronary$687
- Nitrex$520
- Resolute$477
- Assure WCD$435
- LUTONIX$401
- FlowTriever$356
- HawkOne$318
- Peripheral Orbital Atherectomy System$271
- Coronary Orbital Atherectomy System$271
- Impella$270
- FLOWSAVER$269
- MO.MA ULTRA$258
- (5044) MCOT$254
How this compares
$56,014 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $370,152 |
| JardianceEmpagliflozin | 258 | $309,872 |
| EntrestoSacubitril/Valsartan | 160 | $214,287 |
| XareltoRivaroxaban | 151 | $139,249 |
| BrilintaTicagrelor | 65 | $49,428 |
| Repatha SureclickEvolocumab | 23 | $20,135 |
| Enoxaparin Sodium | 18 | $8,038 |
| Metoprolol Succinate | 620 | $7,068 |
| Praluent PenAlirocumab | 13 | $6,630 |
| Atorvastatin Calcium | 501 | $5,064 |
| ClopidogrelClopidogrel Bisulfate | 373 | $3,327 |
| Ezetimibe | 190 | $2,189 |
| Cilostazol | 113 | $2,185 |
| Midodrine Hcl | 32 | $2,051 |
| Amlodipine Besylate | 411 | $2,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $320 | $370,152357 claims |
| Boehringer IngelheimJardiance | $153 | $309,872258 claims |
| NovartisEntresto | $737 | $214,287160 claims |
| Johnson & JohnsonXarelto | $235 | $139,249151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Gretna
- Michael CastineGretna$30K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.